Spots Global Cancer Trial Database for A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Official Title: A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Study ID: NCT00355238
Conditions
Interventions
Study Description
Brief Summary: The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City Of Hope National Medical Center, Duarte, California, United States
City Of Hope National Medical Center, Duarte, California, United States
Harbor UCLA Medical Center, Los Angeles, California, United States
Harbor-Ucla Medical Center, Los Angeles, California, United States
Christiana Care Health Services, Newark, Delaware, United States
University Of Miami Miller School Of Medicine, Miami, Florida, United States
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
University Of Chicago, Chicago, Illinois, United States
University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
Wayne State University, Detroit, Michigan, United States
Saint Louis University, Saint Louis, Missouri, United States
The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States
Duke University Medical Center, Durham, North Carolina, United States
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
Univ Of Texas Southwestern, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Md Anderson Cancer Center, Houston, Texas, United States
Medical College Of Wisconsin, Milwaukee, Wisconsin, United States
Local Institution, Marseille, , France
Local Institution, Reims Cedex, , France
Local Institution, Rennes, , France
Local Institution, Villejuif, , France
Local Institution, Shatin, Nt.,, , Hong Kong
Local Institution, Gyeonggi-Do, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Seoul, , Korea, Republic of
Local Institution, Nilai, Negeri Sembilan, Malaysia
Local Institution, Kuala Lumpur, , Malaysia
Local Institution, Cebu City, , Philippines
Local Institution, Davao City, , Philippines
Local Institution, Quezon, , Philippines
Local Institution, Singapore, , Singapore
Local Institution, Singapore, , Singapore
Local Institution, Tainan, , Taiwan
Local Institution, Taipei, , Taiwan
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
